Analysis of Brexit impact on UK pharma



An overview of what could happen with R&R, approvals, pricing & reimbursement and pharma jobs in the UK because of Brexit

Slides in the pack:

  1. Brexit may re-forge the European life sciences sector’s political landscape
  2. The EMA may be relocated, affecting the European market access procedure
  3. There may be ramifications for the British market if the EMA exits the picture
  4. The exit of UK – EU synergy might negatively affect the life sciences industry in Europe
  5. The impact on the UK reimbursement decision process will likely be minimal
  6. Effects on the Intellectual Property landscape and the TTIP
  7. The UK pharmaceutical industry may lose its leading position in Europe
  8. Sad news for the UK biotech scene?
Reviews (0)


There are no reviews yet.

Be the first to review “Analysis of Brexit impact on UK pharma”

Your email address will not be published. Required fields are marked *